Patent classifications
C07D309/04
Immunoregulatory agents
Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
Immunoregulatory agents
Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
Benzoylglycine Derivatives and Methods of Making and Using Same
Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.
##STR00001##
Benzoylglycine Derivatives and Methods of Making and Using Same
Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.
##STR00001##
BENZENE DISULFONAMIDE FOR THE TREATMENT OF CANCER
The present invention relates to novel substituted benzene disulfonamides, as well as pharmaceutical compositions containing at least one of these substituted benzene disulfonamides together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said substituted benzene disulfonamides are binding to the prenyl binding pocket of PDE6 and therefore, are useful for the prophylaxis and treatment of cancer by inhibition of the binding of PDE6 to farnesylated Ras proteins and thereby, inhibition of oncogenic Ras signaling in cells.
SSAO inhibitors and use thereof
The application relates to a compound of Formula (I) or (I): ##STR00001##
or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of Formula (I) or (I), and a method of treating or preventing a disease in which SSAO plays a role.
AROMATIC ISOTHIOCYANATES
The present invention relates to a compound of formula G
##STR00001##
as defined in claim 1, to a liquid crystal medium comprising a compound of formula G and to high-frequency components comprising these media, especially microwave components for high-frequency devices, such as devices for shifting the phase of microwaves, tunable filters, tunable metamaterial structures, and electronic beam steering antennas, e.g. phased array antennas.
AROMATIC ISOTHIOCYANATES
The present invention relates to a compound of formula G
##STR00001##
as defined in claim 1, to a liquid crystal medium comprising a compound of formula G and to high-frequency components comprising these media, especially microwave components for high-frequency devices, such as devices for shifting the phase of microwaves, tunable filters, tunable metamaterial structures, and electronic beam steering antennas, e.g. phased array antennas.
Substituted tetrahydropyrans as CCR2 modulators
Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (I): ##STR00001##
and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of CCR2 receptors.
Benzenesulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (RORγ(T))
Benzenesulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonist of retinoid-related orphan receptor gamma (RORt) are described. A pharmaceutical composition including such compounds, as well as the use thereof for the topical and/or oral treatment of RORt receptor-medicated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.